TREM2 and neurodegenerative disease.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

48 citing papers in PubMed.

1. An Altered Relationship between Soluble TREM2 and Inflammatory Markers in Young Adults with Down Syndrome: A Preliminary Report.Journal of immunology (Baltimore, Md. : 1950) · 2020
   Trial
2. Microglia and immune signaling as architects of the brain.Frontiers in cellular neuroscience · 2026
   Review
3. Astrocytic KFrontiers in aging neuroscience · 2026
   Review
4. The late-onset Alzheimer's disease risk factor RHBDF2 is a modifier of microglial TREM2 proteolysis.Life science alliance · 2025
   Article
5. Microglia, Trem2, and Neurodegeneration.The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry · 2025
   Review
6. Frontotemporal dementia presentation in patients with heterozygous p.H157Y variant ofJournal of medical genetics · 2023
   Article
7. Friend turned foe: TREM2 agonist in battles against tau.The Journal of experimental medicine · 2023
   Article
8. Identification of the minimal active soluble TREM2 sequence for modulating microglial phenotypes and amyloid pathology.Journal of neuroinflammation · 2021
   Article
9. Impaired Iron Homeostasis and Haematopoiesis Impacts Inflammation in the Ageing Process in Down Syndrome Dementia.Journal of clinical medicine · 2021
   Article
10. Small molecule therapeutics for neuroinflammation-mediated neurodegenerative disorders.RSC medicinal chemistry · 2021
    Review
11. Lack of association between TREM2 rs75932628 variant and amyotrophic lateral sclerosis.Molecular biology reports · 2021
    Article
12. Higher CSF sTREM2 and microglia activation are associated with slower rates of beta-amyloid accumulation.EMBO molecular medicine · 2020
    Article
13. Importance of γ-secretase in the regulation of liver X receptor and cellular lipid metabolism.Life science alliance · 2020
    Article
14. Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease.Science translational medicine · 2019
    Article
15. SILK studies - capturing the turnover of proteins linked to neurodegenerative diseases.Nature reviews. Neurology · 2019
    Review
16. Could Alzheimer's Disease Originate in the Periphery and If So How So?Molecular neurobiology · 2019
    Review
17. Choroid Plexus Acts as Gatekeeper for TREM2, Abnormal Accumulation of ApoE, and Fibrillary Tau in Alzheimer's Disease and in Down Syndrome Dementia.Journal of Alzheimer's disease : JAD · 2019
    Article
18. Next Generation Sequencing Analysis in Early Onset Dementia Patients.Journal of Alzheimer's disease : JAD · 2019
    Article
19. Microglial priming in Alzheimer's disease.Annals of translational medicine · 2018
    Review
20. Amyloid-beta modulates microglial responses by binding to the triggering receptor expressed on myeloid cells 2 (TREM2).Molecular neurodegeneration · 2018
    Article

Corrections and comments

• Comment on
  TREM2 variants in Alzheimer's disease.2013
• Comment on
  TREM2 and neurodegenerative disease.2013

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as